RO7446603 + faricimab

**RO7446603 + faricimab** is an experimental combination therapy being studied primarily for the treatment of diabetic macular edema. RO7446603 is a novel investigational drug (details of its structure or mechanism still under study), and faricimab is a bispecific monoclonal antibody targeting both angiopoietin-2 and VEGF-A pathways to promote vascular stability and reduce retinal edema. In clinical trials, the two agents are co-mixed and administered as a single intravitreal injection, aiming to assess additive or synergistic effects on efficacy and duration of action. The combination is under investigation in early-phase (Phase 1/2) randomized, controlled studies in participants with diabetic macular edema, with the primary focus on safety, tolerability, pharmacokinetics, and efficacy parameters[1][3][5][7][8].